title: Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.
abstract: OBJECTIVE
  We aimed to evaluate the alteration of cardiovascular and metabolic risk parameters of polycystic ovary syndrome (PCOS) patients after a 6-month treatment with an oral contraceptive (OC) containing cyproterone acetate (CPA).
  
  
  METHODS
  Forty women with PCOS were evaluated at baseline and after treatment with an OC. Carotid intima-media thickness (CIMT), brachial artery flow-mediated dilatation (FMD), nitrate-mediated dilatation (NMD), high sensitive (hs)-CRP, lipid levels, index of glucose sensitivity, and homeostasis model assessment of insulin resistance index (HOMA) were assessed.
  
  
  RESULTS
  Mean CIMT was significantly elevated (0.03 ± 0.01 mm) (p < 0.05). There was a tendency of reduction in FMD, which was significant among overweight patients (p < 0.05). Total cholesterol, low-density lipid (LDL), and triglyceride levels were significantly elevated (p < 0.05).
  
  
  CONCLUSIONS
  CIMT as an indicator of early atherosclerosis and FMD as a finding of endothelial dysfunction seem to be deteriorated especially in overweight PCOS patients who were prescribed to OC containing cyproterone acetate for 6 months.
authors.affiliation: Department of Obstetrics and Gynecology, Dokuz Eylul University Medical School, Dokuz Eylul University Hospital, 35210 Balcova, Izmir, Turkey. funda.gode@gmail.com
authors.forename: Funda
authors.initials: F
authors.lastname: Gode
authors.forename: Cigdem
authors.initials: C
authors.lastname: Karagoz
authors.forename: Cemal
authors.initials: C
authors.lastname: Posaci
authors.forename: Bahadir
authors.initials: B
authors.lastname: Saatli
authors.forename: Didem
authors.initials: D
authors.lastname: Uysal
authors.forename: Mustafa
authors.initials: M
authors.lastname: Secil
authors.forename: Bahri
authors.initials: B
authors.lastname: Akdeniz
mesh_terms: D001783:Blood Flow Velocity; D001786:Blood Glucose; D001916:Brachial Artery; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000503:physiopathology; D059168:Carotid Intima-Media Thickness; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D003534:Cyproterone / Q000008:administration & dosage* / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors; D013739:Testosterone / Q000097:blood; D014280:Triglycerides / Q000097:blood; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003277:Contraceptives, Oral, Combined; D014280:Triglycerides; D013739:Testosterone; D004997:Ethinyl Estradiol; D002784:Cholesterol; D003534:Cyproterone